ERBB2 and neoplasm: Additional interesting fields of systems biology applied to cancer immunotherapy also are the identification of drug resistance mechanisms to established novel therapies, and finding correlation of such tumor markers with given amenable targets for immunotherapy (e.g., HER2 with adenosine purinergic pathway) [10, 11].